Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03XTY
|
|||
| Former ID |
DIB000166
|
|||
| Drug Name |
APR-246
|
|||
| Synonyms |
Eprenetapopt
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1] | |
| Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 1/2 | [2] | ||
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 1/2 | [2] | ||
| Esophageal cancer [ICD-11: 2B70; ICD-9: 150] | Phase 1 | [1] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Preclinical | [3] | ||
| Company |
Aprea Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H17NO3
|
|||
| Canonical SMILES |
COCC1(C(=O)C2CCN1CC2)CO
|
|||
| InChI |
1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3
|
|||
| InChIKey |
BGBNULCRKBVAKL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 5291-32-7
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health. | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030246) | |||
| REF 4 | APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.